|
Contraindications
Monotherapy in the treatment of asthma. Treatment of status asthmaticus, other acute episodes of asthma or COPD.
|
|
Special Precautions
Patient w/ CV disease, CNS disorders, DM, hyperthyroidism, hypokalaemia, seizure disorders, ketoacidosis. Not intended for the relief of acute bronchospasm. Hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor pulmonary function, BP, heart rate, CNS stimulation, hepatic function; glucose and K levels.
|
|
Adverse Reactions
Asthma: Headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis. COPD: Cough, headache, musculoskeletal pain, throat irritation, viral resp infection.
Potentially Fatal: Paradoxical bronchospasm. |
|
Drug Interactions
Increased risk of CV effects w/ potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir). Reduced bronchodilatory effect w/ β-blockers. Increased risk of hypokalaemia w/ non K-sparing diuretics. MAOIs and TCAs may potentiate the effect of salmeterol on vascular system.
|
|
CIMS Class
|
|
ATC Classification
R03AC12 - salmeterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
|
Sign Out
